Prescribing trends and drug budget impact of the ARBs in the UK

Value in Health

Volumn 12, Issue 2, 2009, Pages 302-308

  Blak, Betina T ^a   Mullins, C Daniel ^b   Shaya, Fadia T ^b   Simoni Wastila, Linda ^b   Cooke, Catherine E ^c   Weir, Matthew R ^d  

^a EPIC   (United Kingdom)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c PosiHealth   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

ARB; Drug budget impact analysis; Drug expenditure; Hypertension; Prescribing trends

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; PRESCRIPTION DRUG;

ARTICLE; DATA BASE; DRUG COST; DRUG MARKETING; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM; BUDGET; CLINICAL PRACTICE; ECONOMICS; HEALTH CARE COST; HEALTH CARE POLICY; HYPERTENSION; MEDICAL LITERATURE; NATIONAL HEALTH SERVICE; PREVALENCE; STATISTICS AND NUMERICAL DATA;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BUDGETS; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; HYPERTENSION; PHARMACOPOEIAS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PREVALENCE; STATE MEDICINE;

EID: 60349099183     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00423.x     Document Type: Article

References (45)

1. Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999 13 : 569 92.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 157 : 2413 46.
3. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999 17 : 293 302.
4. Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged ≥65 years with mild to moderate hypertension. Clin Ther 2000 22 : 1213 24.
5. Kloner RA, Weinberger M, Pool JL, et al. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol 2001 87 : 727 31.
6. Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999 53 : 175 8.
7. Cuspidi C, Muiesan ML, Valagussa L, et al. CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002 20 : 2293 300.
8. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997 349 : 747 52.
9. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000 355 : 1582 7.
10. Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. J Hypertens 1999 17 : 129 36.
11. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003 21 : 875 86.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 : 995 1003.
13. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 : 1004 10.
14. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000 321 : 1440 4.
15. Praga M, Andrade CF, Luno J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003 18 : 1806 13.
16. British National Formulary 49 (March edn). London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005.
17. Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf 2003 26 : 707 20.
18. British National Formulary 30 (September edn). London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 1995.
19. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001 19 : 609 21.
20. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices - Budget Impact Analysis. Value Health 2007 10 : 336 47.
21. Beard K. Systems for evaluation of new drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2001 10 : 439 43.
22. Drummond M, Laupacis A, Fullerton P. The value of post launch studies - what is desirable versus what is feasible? ISPOR 9th Annual International Meeting Program (Issue Panels) 2004;54.
23. Mullins CD, Wang J, Palumbo FB, et al. The impact of pipeline drugs on drug spending growth. Health Aff 2001 20 : 210 15.
24. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol drug saf 2006 16 : 393 401.
25. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. The performance of the QRISK cardiovascular risk prediction algorithm in an external UK sample of patients from general practice: a validation sample. Heart 2008 94 : 34 9.
26. Blak BT, Thompson M, Bourke A. National Representativeness and Data Quality of the Health Improvement Network (THIN) Database of Primary Care Information for Epidemiological Research. 9th Annual Conference of the UK Federation of Primary Care Research Organisations. Podium presentation. Liverpool, UK, Novermber 2006.
27. Chemist & Druggist Monthly Pricelist January 2005. Kent, CMP Information Ltd. Tonbridge, 2005.
28. Reuter L. UK body calls for better hypertension treatment, 2004. Available from: http://www.healthypages.net/news.asp?newsid=4525 [Accessed May 2007 MI, Greenfield SM, Bradley CP. Prescribing new drugs; qualitative study of influences on consultants and General Practitioners. BMJ 2001 323 : 1 7.
29. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects oflosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 345 : 861 9.
30. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 345 : 851 60.
31. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345 : 1667 75.
32. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 349 : 1893 906.
33. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 362 : 777 81.
34. British National Formulary 53 (March edn). London, British Medical Association and Royal Pharmaceutical Society of Great Britain, 2007.
35. National Institute for Health and Clinical Excellence (NICE) guideline. Management of Type 2 diabetes - Renal disease, prevention and early management. National clinical guideline for diagnosis and management in primary and secondary care, 2002. Available from: http://www.nice.org.uk/page.aspx?o=39385 [Accessed August 17, 2005 B, Poulter NR, Brown MJ, et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 18 : 139 85.
36. Burstall ML. The management of the cost and utilisation of pharmaceuticals in the United Kingdom. Health Policy 1997 41 (Suppl S27 43.
37. Rogers EM. Diffusion of Innovation (3rd edn). New York : The Free Press, 1983.
38. The Department of Health. Quality and outcomes framework. Available from: http://www.dh.gov.uk/en/Policyandguidance/Organisationpolicy/Primarycare/ Primarycarecontracting/QOF/index.htm [Accessed August 15, 2007 SE. General practice fundholding in the United Kingdom. Do not copy. Can Fam Physician 2003 49 : 279 81, 287-9.
39. Majeed A, Malcolm L. Unified budgets for primary care groups. BMJ 1999 318 : 772 6.
40. The National Audit Office (NAO). Tackling obesity in England. Report by the Comptroller and Auditor General HC 220 Session 2000-2001, 15 February, 2001
41. Nair RR, Bollu VK, Blake SG. Healthcare resource utilization by patients with essential hypertension. Value Health 2004 7 : 325.
42. Sever P, Beevers G, Bulpitt C, et al. Management Guidelines in Essential Hypertension: report of the Second Working Party of the British Hypertension Society. BMJ 1993 306 : 983 7.
43. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003 17 : 81 6.
44. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States Review. Arch Intern Med 1995 155 : 829 37.
45. Knight EL, Glynn RJ, Levin R, et al. Failure of evidence-based medicine in the treatment of hypertension in older patients. JGlM 2000 15 : 702 9.